Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Nov 26 2021 12:00
    57,107.15 -1,687.94 (-2.87%)
  • NIFTY Nov 26 2021 12:00
    17,026.45 -509.80 (-2.91%)
  • SENSEX Nov 26 2021 12:00
    57,107.15 -1,687.94 (-2.87%)
  • NIFTY Nov 26 2021 12:00
    17,026.45 -509.80 (-2.91%)
  • Nasdaq Nov 27 2021 04:30
    15,491.66 -353.57 (-2.23%)
  • DJIA Nov 27 2021 04:30
    34,899.34 -905.04 (-2.53%)
  • S&P 500 Nov 27 2021 04:30
    4,594.62 -106.84 (-2.27%)
  • Hang Seng Nov 26 2021 02:10
    24,080.52 -659.64 (-2.67%)
  • Crude Oil Nov 26 2021 11:54
    5,161.00 -676.00 (-11.58%)
  • Gold Nov 26 2021 11:54
    47,640.00 +219.00 ( +0.46%)
  • Silver Nov 26 2021 11:54
    62,119.00 -1,031.00 (-1.63%)
  • Copper Nov 26 2021 11:17
    728.00 -15.35 (-2.06%)
  • Pound / Rupee Dec 23 2016 22:30
    99.19 -0.17 (-0.17%)
  • Dollar / Rupee Dec 23 2016 22:30
    74.42 +0.01 ( +0.01%)
  • Euro / Rupee Dec 23 2016 22:30
    83.45 -0.02 (-0.02%)
  • Yen / Rupee Dec 23 2016 22:30
    0.65 0.00 (-0.13%)

BSE Code : | NSE Symbol : | ISIN:| SECTOR : |

NSE BSE
 

Volume 280564

Prev. Close

Open Price

Bid Price (QTY)

Offer Price (QTY)

 

Today’s High/Low -

52 wk High/Low -

Key Stats

MARKET CAP (RS CR) 17.47
P/E 9.21
BOOK VALUE (RS) 66.0331343
DIV (%) 0
MARKET LOT 1
EPS (TTM) 5.66
PRICE/BOOK 0.789755030604385
DIV YIELD.(%) 0
FACE VALUE (RS) 10
DELIVERABLES (%)
4

News & Announcements

14-Nov-2021

N G Industries reports standalone net profit of Rs 0.40 crore in the September 2021 quarter

21-Oct-2021

NG Industries to table results

25-Sep-2021

N G Industries Ltd - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)

26-Aug-2021

N G Industries Ltd - Announcement under Regulation 30 (LODR)-Newspaper Publication

21-Oct-2021

NG Industries to table results

24-Aug-2021

NG Industries AGM scheduled

22-Jul-2021

NG Industries to announce Quarterly Result

18-Jun-2021

NG Industries to conduct board meeting

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Aashka Hospitals Ltd 543346
Adeshwar Meditex Ltd 543309
Advanced Micronic Devices Ltd 517552
Apollo Hospitals Enterprise Ltd 508869 APOLLOHOSP
Artemis Global Life Sciences Ltd((Merged) 540616 AGLSL
Artemis Medicare Services Ltd 542919 ARTEMISMED
Aspira Pathlab & Diagnostics Ltd 540788
Aster DM Healthcare Ltd 540975 ASTERDM
Casil Health Products Ltd(merged) 523254
CDR Health Care Ltd 523353
Centenial Surgical Suture Ltd 531380
Chennai Meenakshi Multispeciality Hospital Ltd 523489
Constronics Infra Ltd 523844
Cure Spects Laser Ltd 531356
Datt Mediproducts Ltd 532171 DATTMEDI
Deccan Hospital Corporation Ltd (Merged) 523258
Dhanvantri Jeevan Rekha Ltd 531043
Digiflex India Ltd 526111
Disposable Medi - Aids Ltd 523540
Dolphin Medical Services Ltd 526504
Dr Agarwals Eye Hospital Ltd 526783
Dr Lal Pathlabs Ltd 539524 LALPATHLAB
Dr Lalchandani Labs Ltd 541299
Emaai Pharma Ltd 524756
Fidelity Industries Ltd (Wound-up) 526425
Fortis Healthcare Ltd 532843 FORTIS
Fortis Malar Hospitals Ltd 523696
Gian Lifecare Ltd 542918
Gil Hospitals Ltd (Wound-up) 526063
Healthcare Global Enterprises Ltd 539787 HCG
Indraprastha Medical Corporation Ltd 532150 INDRAMEDCO
Iswar Medical Services Ltd 507480 ISWARMEDIC
Kemwell International Ltd 530827
Keshlata Cancer Hospital Ltd 40450
Kids Medical Systems Ltd 540812
KMC Speciality Hospitals (India) Ltd 524520
Kovai Medical Center & Hospital Ltd 523323 KOVAI
Krishna Institute of Medical Sciences Ltd 543308 KIMS
Krsnaa Diagnostics Ltd 543328 KRSNAA
La Medical Devices Ltd (Wound-up) 524772
Lifeline Injects Ltd 523379
Lokmanya Industries Ltd 526421
Looks Health Services Ltd 534422
Lotus Eye Hospital & Institute Ltd 532998 LOTUSEYE
Maestros Mediline Systems Ltd 501209
Max Healthcare Institute Ltd 543220 MAXHEALTH
Medinova Diagnostic Services Ltd 526301
Metropolis Healthcare Ltd 542650 METROPOLIS
Monozyme India Ltd 522199
Narayana Hrudayalaya Ltd 539551 NH
New World Medical (India) Ltd 524496
Nidan Laboratories & Healthcare Ltd 535411 NIDAN
Noida Medicare Centre Ltd 523670
Nova Surgikos Ltd 524762
Opto Circuits (India) Ltd 532391 OPTOCIRCUI
Poly Medicure Ltd 531768 POLYMED
Pramila Kidney Hospitals Ltd 40265
Prevest Denpro Ltd 543363
Raaj Medisafe India Ltd 524502
Regency Hospital Ltd 526403
Safire Global Medicare Ltd 524418 CDRMEDICAL
Sangam Health Care Products Ltd 531625
Scandent Imaging Ltd 516110
Secunderabad Healthcare Ltd 524540
Shalby Ltd 540797 SHALBY
Sharma East India Hosp and Medical Research Ltd 524548
Shiva Medicare Ltd 524602
Shree Pacetronix Ltd 527005
Siemens Healthcare Diagnostics Ltd(merged) 506559
Soni Medicare Ltd 539378
Sterling (Gujarat) Hospitals Ltd 531741
Surgiplast Ltd 523077
Surlux Diagnostic Ltd 507854
Surlux Health Centres Ltd 523265
Surlux Mediquip Ltd 523515
Tamilnad Hospital Ltd 523443
Tejnaksh Healthcare Ltd 539428
Thyrocare Technologies Ltd 539871 THYROCARE
Transgene Biotek Ltd 526139
Transmedica (India) Ltd 526461
Transpact Enterprises Ltd 542765
Twenty First Century Medicare Ltd 40212
United Diagnostic International Ltd 523485
Vijaya Diagnostic Centre Ltd 543350 VIJAYA

Share Holding

Category No. of shares Percentage
Total Foreign 10302 0.31
Total Institutions 0 0.00
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 14175 0.42
Total Promoters 2496000 74.50
Total Public & others 830023 24.77
Total 3350500 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About N G Industries Ltd

N G Industries Ltd is an India-based company. The Company is engaged in providing medical services. The Companys divisions include N. G. Medicare & Calcutta Hope Infertility Clinic, N. G. Nursing Home and N. G. Pharmacy. The Company has set up laboratory for conducting research and development in the field of embryology and diagnostics. N. G. Medicare is approved for cashless services for patients admitted under various health insurance schemes. The Company's nursing home services include ultrasonography, radiodiagnosis, gastroscopy, colonoscopy, bronchoscopy, laparoscopic surgeries, endoscopic surgeries, laparoscopic cholecystectomy, cosmetic Surgeries, arthroscopy, haematology and gynaecological surgeries. N G Industries Ltd was established in 1994 as a new Company to foray into the Healthcare sector at a time when few private sector such initiatives had come up. Their first Division-'N G Medicare & Calcutta Hope Infertility Clinic' came into operation in December 1995 as a complete Diagnostic Centre with Daycare and Nursing Home facilities providing a wide range of Medical Services in fields of Pathology, Radiology, Cardiology, Gastroenterology, Infertility ,Minimal Invasive Surgeries as well as a Multispeciality Clinic. N G Medicare within a couple of years made a mark for itself in the city and was a well known brand in healthcare services in Kolkata as well as suburbs and specially in South Kolkata was termed as the Best In South. In 2006 the Company started its second Division in the name of 'N G Nursing Home'-a 53 Bedded Indoor establishment in South Kolkata and thereby extended its services to major Surgeries including General Surgery, Joint Replacements, Urology etc. It also housed an Intensive Care Unit. In 2007 the Company launched its third division 'N G Pharmacy' and has now two retail Pharmacy outlets located in South Kolkata. The Company has thus established itself as a comprehensive Healthcare Delivery Organisation providing services ranging from Clinics, Diagnostics, Inpatient & Outpatient Services as well as Pharmacy dispensing. The Company has an excellent track record of uninterrupted Dividend payouts, efficient & Ethical management, Debt free operations and sustained growth. The Company looks forward to further growth with excellence performance in its Mission which it is confident will result in enhanced shareholder value.

N G Industries Ltd Chairman Speech

N G Industries Ltd Company History

N G Industries Ltd is an India-based company. The Company is engaged in providing medical services. The Companys divisions include N. G. Medicare & Calcutta Hope Infertility Clinic, N. G. Nursing Home and N. G. Pharmacy. The Company has set up laboratory for conducting research and development in the field of embryology and diagnostics. N. G. Medicare is approved for cashless services for patients admitted under various health insurance schemes. The Company's nursing home services include ultrasonography, radiodiagnosis, gastroscopy, colonoscopy, bronchoscopy, laparoscopic surgeries, endoscopic surgeries, laparoscopic cholecystectomy, cosmetic Surgeries, arthroscopy, haematology and gynaecological surgeries. N G Industries Ltd was established in 1994 as a new Company to foray into the Healthcare sector at a time when few private sector such initiatives had come up. Their first Division-'N G Medicare & Calcutta Hope Infertility Clinic' came into operation in December 1995 as a complete Diagnostic Centre with Daycare and Nursing Home facilities providing a wide range of Medical Services in fields of Pathology, Radiology, Cardiology, Gastroenterology, Infertility ,Minimal Invasive Surgeries as well as a Multispeciality Clinic. N G Medicare within a couple of years made a mark for itself in the city and was a well known brand in healthcare services in Kolkata as well as suburbs and specially in South Kolkata was termed as the Best In South. In 2006 the Company started its second Division in the name of 'N G Nursing Home'-a 53 Bedded Indoor establishment in South Kolkata and thereby extended its services to major Surgeries including General Surgery, Joint Replacements, Urology etc. It also housed an Intensive Care Unit. In 2007 the Company launched its third division 'N G Pharmacy' and has now two retail Pharmacy outlets located in South Kolkata. The Company has thus established itself as a comprehensive Healthcare Delivery Organisation providing services ranging from Clinics, Diagnostics, Inpatient & Outpatient Services as well as Pharmacy dispensing. The Company has an excellent track record of uninterrupted Dividend payouts, efficient & Ethical management, Debt free operations and sustained growth. The Company looks forward to further growth with excellence performance in its Mission which it is confident will result in enhanced shareholder value.

N G Industries Ltd Directors Reports

TO THE MEMBERS:

Your Directors have pleasure in presenting the 27th Annual Report on the affairs of the Company together with the Audited Financial Statements for the financial year ended on 31st March, 2021.

FINANCIAL RESULTS

The financial results of the Company for the year ended 31st March, 2021 is summarized below:

Particulars 2020-21 2019-20
(Rs. in lakhs) (Rs. in lakhs)
Income from Operations 1188.36 1850.16
Other Income 14.16 (04.42)
Total Income 1202.52 1845.74
Total Expenditure 1119.25 1643.02
Profit before Taxation 83.27 202.72
Less Tax Expenses 21.89 56.09
Profit afterTax 61.38 146.63
Earnings per Share (?) 1.83 4.38

OPERATIONS AND PROSPECTS :

As we report today, the country is emerging from the ravages of the second wave of Covid-19 pandemic. Our country as well as rest of the world is trying to adapt and fight the challenges posed by the pandemic in all possible ways with only a small part of our population vaccinated so far and the fears expressed by the scientific and medical community about the possibility of the third wave coming, it is clear that we are still in the midst of an unprecedented pandemic, never the likes of which has been experienced by the modern world and the uncertainties of its impact in all ways and its timelines for future are not known to us .

The company had released a detailed disclosure last year regarding its experience under Covid-19 lockdown and the consequent impact of this pandemic on the company's operations and although a very eventful year has gone by, we find when we visit that disclosure again, it still remains as relevant today especially with fresh new lockdowns following the second wave, back to severe restrictions and operating constraints, big setback for Clinics, elective treatments & surgeries, preventive healthcare, falling footfalls everywhere, and uncertainty of the evolving future.

The Company achieved quarter to quarter recovery in terms of operating revenues close to 90% of pre-Covid levels in the fourth quarter. However, there still remain major deficits especially in our retail services of OPD and Clinics which will take time to recover. However, the second wave of the pandemic having hit us in late March-April 2021, has put us, in India in a spot very similar to the disrupted and uncertain period of last year.

In the healthcare sector, we had to rediscover our ways and means of functioning by establishing a thorough and well-rehearsed safety norms and other protocols. These protocols include encouraging patients to take an appointment before a visit to the premises, enabling cashless payment, sanitizing them before entering the premises, allowing limited number of persons inside, compulsory use of face masks, thermal scanning for all who are entering the premises, distancing in waiting areas, visitor restrictions etc. We had to put in place, proper measures for biosafety and sanitization in all our premises, provide gloves, masks and other appropriate protective gear for different functional employees. We have invested in installations, consumables, awareness campaign materials, training to instill confidence in our staff, doctors as well as patients. Later during the year, we could vaccinate all our employees as well. We had to create isolation floors, create ICU beds for those in isolation as well as increase oxygenation beds. These resulted in higher operational costs with reduced capacities in terms of operational facilities.

Under prevailing circumstances, the company had to navigate its operations under extremely challenging circumstances, keeping in mind its priority of keeping its employees safe and protected, while sustaining services wherever possible. Challenges included transporting staff and supplies during lockdowns, running an indoor establishment 24 by 7 under such situations, operating with low patient footfalls and admissions, many doctors not choosing to hold regular clinics, outpatient services/clinic as well as preventive healthcare services and elective surgeries all falling to very, very low levels. Covid care was the priority for the nation but for non Covid treatment establishments like ours, we too faced very difficult times. People at any cost would want to stay away from stepping into a medical setup.

The company adopted all possible measures of prudent cost control management and operated with great emphasis on service without frills and with the immediate strategy to conserve resources for very uncertain times and ensure that we continue to serve our citizens ethically, to ensure that our employees are safe and their livelihood is secure and that the company's financial position remains sound and debt free and ready to take off once the pandemic is under control. Your Company's Whole time Director chose not to avail of his salary for the year in this endeavor.

The Company has introduced new Covid related pathological tests to its menu to help citizens avail of the same. We have started Covid Rapid Antigen test as well as test for Covid Antibodies. During April 2021, we got both our establishments approved as vaccination centers and carried out vaccinations from the government supplied Covishield as well as Covaxin vaccines. We have put in place infrastructure and manpower for carrying out vaccination as a regular activity at both our establishments.

Covid-19 pandemic has affected your company's revenues and profitability for the year and continues to do so at present, although to different measures at different times. We consider your company's performance for the year 2020-21 as satisfactory in the context of the prevailing pandemic and believe that the outlook of the company can be one of recovery and to be soon in line with its earlier consistent performance, once the country as a whole is able to put behind the Covid-19 pandemic. The Company is in the medium term, geared up with suitable strategies and policies to sustain the challenges posed by this Covid-19 pandemic and to protect the interests of all its stakeholders, having now the benefit of more knowledge and experience of the pandemic.

There was no change in the nature of the business of the Company during the year.

DIVIDEND AND TRANSFER TO RESERVE:

In the prevailing circumstances, conserving funds is felt to be prudent. In this context, your Directors have felt that the profit for the financial year ended 31st March, 2021, have been inadequate and therefore your Directors have not recommended any dividend for the year. The board has taken this course so that the company remains financially strong and can, if required deploy conserved funds for any eventualities that may pose challenges to its operation in the present prevailing pandemic. Also, the Board of Directors of the Company has decided not to transfer any amount to the Reserves for the year under review

TRANSFER OF DIVIDEND AND CORRESPONDING EQUITY SHARES TO INVESTOR EDUCATION AND PROTECTION FUND:

In accordance with the provisions of Sections 124 and 125 of Companies Act, 2013 and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016 (IEPF Rules), dividends not encashed / claimed within seven years from the date of transfer to unpaid dividend account are to be transferred to the Investor Education and Protection Fund (IEPF) Authority.

The IEPF Rules mandate Companies to transfer shares of Members whose dividends remain unpaid / unclaimed for a continuous period of seven years to the demat account of IEPF Authority. The Members whose dividend / shares are transferred to the IEPF Authority can claim their shares / dividend from the Authority. In accordance with the said IEPF Rules and its amendments, the Company had sent notices to all the Shareholders whose shares were due to be transferred to the IEPF Authority and simultaneously published newspaper advertisement. List of such shareholders are also posted on the website (www.nqind.com) of the Company.

In terms of the provisions of Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016, Rs.89,555 of unpaid / unclaimed dividends and 621 shares were transferred during the financial year 2020-21 to the Investor Education and Protection Fund.The Company has uploaded the details of unpaid and unclaimed amounts lying with the Company as on 31st March, 2020 on the Company's website at www.ngind.com and on the website of the Ministry of Corporate Affairs at www.iepf.gov.in.

DETAILS OF DEMAT/UNCLAIMED SUSPENSE ACCOUNT:

The Company does not have any shares in the demat suspense account or unclaimed suspense account.

DISCOUNT TO SHAREHOLDERS :

The Company has decided to offer a discount of 15% to all shareholders of the Company on all the diagnostic services being offered by us. The shareholders availing the discount will be required to state their Folio number/DP ID and produce only identity documents.

AUDITORS:

M/s. Pushpendra Jain & Co., Chartered Accountants, Kolkata, (Firm Registration No. 320233E) holds office of the Auditors of the Company until the conclusion of the ensuing 27th AGM of the Company. Accordingly, the Company is required to appoint new Auditors in place of the retiring Auditors.

The Board of Directors on the recommendation of the Audit Committee has recommended to the members of the Company for appointment of M/s B. N. Jha & Associates, Chartered Accountant, Kolkata (Firm Registration No. 331925E) as Statutory Auditors of the Company for a term of one year commencing from the conclusion of the 27th AGM till the conclusion of the 28th AGM.

AUDITORS' REPORT :

The Auditors' Report on the financial Statement of the Company forms part of the Annual Report. There is no qualification, reservation, adverse remark, disclaimer or modified opinion in the Auditors' Report, which calls for any further comments or explanations. Further during the year under review, the Auditors have not reported any matter under section 143(12) of the Companies Act, 2013, and therefore no details are required to be disclosed pursuantto Section 134(3)(ca) of the CompaniesAct, 2013.

DIRECTORS & KEY MANAGERIAL PERSONNEL :

Your Directors has recommended the re-appointment of Mr Rajesh Goenka as Whole-time Director of the Company for a period of three years from 01.09.2021 to 31.08.2024 subject to approval of the Shareholders at the ensuing Annual General Meeting.

Ms. Neha Goenka, Director of the Company, retires by rotation and being eligible, offers herself for re-appointment in the ensuing Annual General Meeting.

Mr Rajesh Goenka, designated as Whole-time-Director & Chairman, Mr. Santosh Kumar Thakur as Chief Financial Officer and Mr. Dipak Kumar Shaw as Company Secretary & Compliance Officer are identified as Key Managerial Personnel of the Company.

SUBSIDIARIES, JOINTVENTURE OR ASSOCIATE COMPANIES :

The Company does not have any Subsidiary / Joint venture or Associate Company within the meaning of the Companies Act, 2013.

WHISTLE BLOWER MECHANISM :

This has been discussed in detailed in Corporate Governance Report forming part of this Report.

LOANS, INVESTMENTAND GUARANTEES BY THE COMPANY :

During the year under review, there is no loan given, investment made, guarantee given or security provided by the Company to any entity under section 186 of the Companies Act, 2013.

MEETINGS OF BOARD :

Four Meetings of the Board of Directors were held during the year. For details relating to composition and dates of meeting please refer to clause 2 of report on Corporate Governance, which forms part of this Annual Report.

DETAILS OF THE COMMITTEE OF DIRECTORS :

Composition of Audit Committee of Directors, Nomination and Remuneration Committee of Directors and Stakeholders Relationship Committee of Directors, number of meetings held of each Committee during the financial year 2020-21 and meeting attended by each member of the Committee as required under the Companies Act, 2013, are provided in Corporate Governance Report forming part of thisAnnual Report.

The Recommendations by the Audit Committee, as and when made, to the Board have been accepted.

DIRECTOR REMUNERATION POLICY:

The Company has followed a Policy on Appointment and Remuneration of Directors, Key Managerial Personnel and senior management personnel. The criteria for determining qualifications, positive attributes, independence of a Director, performance evaluation of Board, Committees and the Directors are laid down under the Nomination and Remuneration Policy of the Company. The performance evaluation of the Board, it's Committees and of individual Directors was made by structured questionnaire and the Directors were satisfied with the evaluation process. Remuneration Policy for Directors, Key Managerial Personnel and other employees of the Company may be accessed on the Company's website at the link: http://www.ngind.com/docs/Nomination%20and%20Remuneration%20Policy.pdf.

The recommendation made by the Nomination and Remuneration Committee were accepted by the Board. The above policy was last amended by Board on 14.02.2020.

DECLARATION OF INDEPENDENCE BY THE INDEPENDENT DIRECTORS:

Pursuant to Section 149(7) of the Companies Act, 2013, Independent Directors of the Company have made a declaration, confirming the Compliance of the Conditions of the independence, stipulated in Section 149(6) of the Act read with Regulation 16(1)(b) of SEBI (LODR) Regulation, 2015.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY :

Internal Audit has been conducted throughout the organization, by qualified outside Internal Auditors. Findings of the Internal Audit Report are reviewed by the top management and by the Audit Committee of the Board and proper follow up action is ensured wherever required. The Statutory Auditors have evaluated the systems of internal controls of the Company and have reported that the same are adequate and commensurate with the size of the Company and nature of its business.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL ) ACT, 2013:

The Company has put in place, an Internal Complaints Ccommittee to redress complaints received regarding sexual harassment from any employee of the Company. The committee comprising of majority of women employees is constituted for the purpose of ensuring compliance towards the provisions of the above Act. During the year 2020-21, no complaints were received by the said committee. The Company's Policy for Prevention, Prohibition and Redressal of Sexual Harassment may be accessed on the Company's Website at the following link

https://ngind.com/docs/Policv%20for%20Prevention,%20Prohibition%20&%2 0Redressal%20of%20sexual%20harassment.pdf.

LISTING WITH STOCK EXCHANGES :

As per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby declares that the Listing of its Shares at The Calcutta Stock Exchange Ltd. as well as at BSE Ltd were continued throughout the year and the Listing Fee due till date stands paid.

DEMATERIALISATION OF SHARES :

In order to facilitate dealing in shares in the electronic mode, your Company has entered into an arrangement with the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). With this, the members have the option to trade their dematerialised shares in the Company through NSDL or CDSL. Securities and Exchange Board of India (SEBI) has made it mandatory for all investors to trade in the shares of the Company in dematerialised form. The Company's Shares have been allotted ISIN:INE825C01018.

The Company has not issued any sweat equity shares, bonus and employee stock option and not called for buyback of shares during the current financial year. Directors also confirm that there are no shares under suspense status.

COST AUDIT :

Cost Audit is not applicable to the Company.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO :

The particulars as prescribed under Section 134(3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules 2014 are as follows

A. CONSERVATION OF ENERGY

(i) The steps taken I impact on conservation of energy;

The operations of the Company, being healthcare, the Company is taking every necessary step to reduce the consumption of energy.

(ii) The steps taken by the Company for utilizing alternate source of energy;

Your Company is exploring the possibility of utilizing alternate sources of energy, which may be taken up for future Implementation when found to be credible and viable.

(iii) The capital investment on energy conservation equipment;

Though investments have been made in areas like change over to LED lights, Energy audits, load balancing, replacement with energy saving air conditioners etc., no specific budgets or heads of such are accounted for, in view of major energy specific project being yet to be taken up.

B. TECHNOLOGY ABSORPTION

The nature of the Company's operations being healthcare, the required information in the prescribed manner is considered to be not applicable to the Company.

C. FOREIGN EXCHANGE EARNINGS & OUTGO

During the year under review, there were no inflows or outgo of Foreign Exchange.

RISK MANAGEMENT:

The provisions relating to composition of a Risk Management Committee are not applicable to the Company.

CORPORATE SOCIAL RESPONSIBILITY:

The provisions relating to Corporate Social Responsibility are not applicable to the Company.

PARTICULARS OF EMPLOYEES & MANAGERIAL REMUNERATION:

Disclosure of Remuneration under Section 197 of the Companies Act, 2013 and Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

I: Ratio of remuneration of each Executive Director to median remuneration of the employees of the Company for the financial year 2020-21, percentage increase in remuneration of Directors, Chief-Financial Officer and Company Secretary during the financial year 2020-21:

SI. No. Name of Director(s)/KMP Designation Ratio of remuneration of director to median employee remuneration Percentage increase in Remuneration
1 Rajesh Goenka Chairman & Whole-time Director _* -
2 Santosh Kumar Thakur CFO - -
3 Dipak Kumar Shaw Company Secretary - 3.15

*Mr. Rajesh Goenka, Whole-time Director of the Company voluntarily chose to not accept any remuneration during the year.

ii: The percentage increase in the median remuneration of Employees for the financial year 2020-21 was Nil.

iii: The Company has 67 permanent employees (excluding Whole-time Director) on the rolls of the Company as on 31st March, 2021

iv It is hereby affirmed that the remuneration paid during the year, is as per the Remuneration Policy of the Company.

DIRECTORS' RESPONSIBILITY STATEMENT :

Your Directors state that:

• In the preparation of the annual accounts for the financial year ended on 31st March, 2021, the applicable accounting standards had been followed along with proper explanation relating to material departures;

• Such accounting policies have been selected and applied consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2021 and of profit of the Company for that period;

• the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

• the annual accounts have been prepared on a going concern basis

• internal financial controls have been laid down so that the same can be followed by the Company and that such internal financial controls are adequate and are operating effectively and

• proper systems have been devised to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

MANAGEMENT DISCUSSION & ANALYSIS

Our discussion & analysis may be perceived as repetitive over the years but constitutes the essence of wisdom about our field of operations as assimilated by us over two decades of experience.

A) INDUSTRY STRUCTURE & DEVELOPMENT:

Rising incomes in the hands of our citizens, increase in health awareness in society at large, increasing population of older citizens, new technologies in the sector, longer life expectancy, health insurance penetration and medical tourism are contributing to the growth in healthcare sector. The new health Insurance scheme announced by the union government, when fully implemented, will further increase penetration of insured healthcare in the country. Reach as well as depth of healthcare will significantly improve in the post Covid era.

Covid-19 is an unprecedented, new, unknown, disruptive development which has hit globally as a whole including all countries, economies, sectors, companies and has affected in more ways than one can imagine and is still unfolding. The Company has released separate disclosure regarding impact of the pandemic and the challenges it has posed and the same is available on our website under "Information & Circulars for Shareholders" We have also discussed it earlier in the Directors Report under ‘Operations and Prospects"

B) OPPORTUNITIES, THREATS, RISKS AND CONCERNS:

Opportunity for the Company is inherent in the sectors we operate in and are already covered in above paragraph (A).

Slowdown in economy, especially in the services or retail sector affects most businesses including healthcare. The healthcare business runs the risk of unfavorable publicity in case of unsuccessful treatment, translating into reduction of patient flow, risk of good professionals leaving the Company and it stands to lose years of, on job training and risk of independent Doctors beginning to refer patients elsewhere.

Healthcare establishments have faced mob violence and damage to property, increased litigation for award of compensation on sometimes frivolous grounds; doctors have been taken to Medical council for action on grounds of negligence etc. This challenge will have to be met by all, with more transparent and diligent services. The pandemic has also added to the major challenges in terms of employee attrition as well as professional changes being adopted by doctors as well as paramedical professionals. It is however too early to assess these challenges at the moment and the company however recognizes these issues as concerns.

The Company mitigates these risks, through adopting ethical practices, transparent dealings with patients and explaining to them, in plain layman's language, the pros and cons of the treatment with realistic assessments of recovery. Quality surveillance and adherence to strict protocols also mitigates risks. The Company provides its professionals, a very good and challenging environment with continuous growth and also looks out to induct new and good professionals to keep strengthening its team. The Company has also adopted external quality audits as well as accreditations. To face competition, the Company keeps close interaction with Doctors and strives to keep services at levels meeting their standards. The Company is also continuously investing in newer technologies and equipment to stay ahead, in offering value added and superior quality oftests at affordable tariffs.

Short term adverse impact of Covid-19 has already been dealt with, in our disclosures available on our website under "Information & Circulars for Shareholders" as well as earlier in the Directors Report under ‘Operations and Prospects."

C) OUTLOOK

Although the Company operates in an industry that is increasingly getting more competitive, the long-term outlook of your Company looks good on account of our adherence to quality of services, affordable tariffs and trust earned, through over two decades of diligent service to citizens. The Company is facing challenges to its image and credibility through consistent credible and transparent dealings and greater communication with patient's families on all aspects of treatment. Covid-19 impact has been indicated in the Company Disclosures released separately and our experience during the year will help us reorient our strategies and adapt ourselves to the current new wave of the pandemic as well as for post Covid-19 ecosystem. Our, over two decades of trust and goodwill will help us move ahead and get the Company's operations back on track soon. Details with regard to Covid-19 have already been dealt with in our disclosures available on our website under "Information & Circulars for Shareholders" as well as earlier in the Directors Report under ‘Operations and Prospects"

D) INTERNAL CONTROL:

Your Company has adequate internal control systems, which commensurate with its size of operations. Please see paragraph with heading ‘internal control systems andtheir adequacy' in this report.

E) HUMAN RESOURCES/INDUSTRIAL RELATIONS:

Your Company has during the previous year continued to have cordial industrial relations with its employees. The number of employees of the Company at the end of the year was 67. Pandemic has led to some employees to leave their jobs out of resulting compulsions and even many Doctors chose not to continue Clinics at our premises.

F) FINANCIAL AND OPERATIONAL PERFORMANCE:

This has already been detailed earlier in this report.

CORPORATE GOVERNANCE :

The Corporate Governance Report forms an integral part of this Report and has been set out as a separate annexure to this Report. The certificate from the Auditors of the company, certifying compliance of conditions of Corporate Governance stipulated in the Listing Agreement with the Stock Exchanges is also annexed to Report on Corporate governance.

CONTRACTS AND ARRANGEMENTS WITH RELATED PARTY :

All contracts / arrangements / transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company had not entered into any contracts / arrangements / transactions with related parties which could be considered material in accordance with the policy of the Company on materiality of related party transactions.

Your Directors draw attention of the members to notes, to the financial statement which sets out related party disclosures.

SECRETARIAL AUDITOR :

The Board has appointed S. Rath & Co., Practicing Company Secretary, to conduct Secretarial Audit for the financial year 2020-21. The Secretarial Audit Report for the financial year ended 31st March, 2021 is annexed herewith to this report.

There are no qualifications in their report requiring explanation from the board.

EXTRACT OF ANNUAL RETURN :

Extract ofAnnual Return of the Company is annexed herewith to this report. DEPOSITS :

The Company has not accepted any deposits from the public during the period under review and accordingly no amount was outstanding as on the date of the Balance Sheet.

SECRETARIAL STANDARDS:

The Company is in compliance with applicable Secretarial Standards issued by the Institute of Company Secretaries of India, New Delhi.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant and material orders passed by the Regulators/Courts that would impact the going concern status of the Company and its future operations.

MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There have been no material changes and commitments, if any, affecting the financial position of the Company which have occurred between the end of the financial year to which the financial statements relate and the date of the report.

ACKNOWLEDGEMENTS:

Your Directors acknowledge the co-operation and assistance received from the Shareholders, Doctors, Banks and various Government Agencies. Your Directors wish to place on record their sincere appreciation for the contribution made by the employees.

   

N G Industries Ltd Company Background

Rajesh Goenka
Incorporation Year1994
Registered Office1st Floor,37 A Southern Avenue
Kolkata,West Bengal-700029
Telephone91-33-24197542,Managing Director
Fax91-33-24646390
Company SecretaryDipak Kumar Shaw
AuditorPushpendra Jain & Co
Face Value10
Market Lot1
ListingBSE,Kolkata,
RegistrarS K Infosolutions Pvt Ltd
34/1 A ,Sudhir Chatterjee St, ,Kolkata - 700006

N G Industries Ltd Company Management

Director NameDirector DesignationYear
Raj Kumar Bajoria Non-Exec. & Independent Dir. 2020
Jagdish Chand Kumbhat Non-Exec. & Independent Dir. 2020
Rajesh Goenka Chairman & Wholetime Director 2020
Neha Goenka Non-Exec & Non-Independent Dir 2020
Dipak Kumar Shaw Company Secretary 2020

N G Industries Ltd Listing Information

N G Industries Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Medical Centre Income NA 00017.66664

Contact us Contact us